Shanghai RAAS Blood Products (002252.SZ): The SR604 injection is proposed to be included in the Care Program - Extension pilot project.

Shanghai RAAS Blood Products (002252.SZ) announced that the Center for Drug Evaluation (CDE) of the National Medical Products Administration has recently issued a public notice, indicating that the company's SR604 injection is proposed to be included in the "Care Program - Extension" pilot project, with the public announcement period ending on September 4, 2026. It is reported that the "Care Program - Extension" project, also known as the Rare Disease Innovative Drug Research and Development Encouragement Pilot Program, aims to encourage innovative drugs to target the clinical treatment needs of rare diseases. The program focuses on addressing scientific issues in the research and development of original innovative drugs for rare diseases, enhancing R&D efficiency. If SR604 injection is formally included in the "Care Program - Extension" pilot project after the public notice period, one of its target indications, "Congenital Factor VII Deficiency," will benefit from close communication and professional guidance from the CDE during the drug clinical development process, promoting attention to patient treatment preferences and experiences, and is expected to facilitate earlier access to the product for patients with "Congenital Factor VII Deficiency."